NASDAQ:IMMP Immutep (IMMP) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free IMMP Stock Alerts $2.33 -0.06 (-2.51%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.30▼$2.4750-Day Range$2.11▼$2.8952-Week Range$1.50▼$3.90Volume112,564 shsAverage Volume181,454 shsMarket Capitalization$204.88 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immutep alerts: Email Address Immutep MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside264.8% Upside$8.50 Price TargetShort InterestBearish1.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.31) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.06 out of 5 starsMedical Sector826th out of 939 stocksPharmaceutical Preparations Industry389th out of 444 stocks 3.5 Analyst's Opinion Consensus RatingImmutep has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Immutep has a forecasted upside of 264.8% from its current price of $2.33.Amount of Analyst CoverageImmutep has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.30% of the outstanding shares of Immutep have been sold short.Short Interest Ratio / Days to CoverImmutep has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Immutep has recently increased by 5.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmutep does not currently pay a dividend.Dividend GrowthImmutep does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMMP. Previous Next 2.5 News and Social Media Coverage News SentimentImmutep has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Immutep this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for IMMP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Immutep to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immutep insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.07% of the stock of Immutep is held by insiders.Percentage Held by InstitutionsOnly 2.32% of the stock of Immutep is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immutep are expected to decrease in the coming year, from ($0.31) to ($0.32) per share.Price to Book Value per Share RatioImmutep has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon Musk’s warning to AmericaUrgent Presidential Warning: Coming election shock could decimate millions of Americans, wiping out their savings and way of life.Go here to learn how to protect wealth and family. About Immutep Stock (NASDAQ:IMMP)Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Read More IMMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMMP Stock News HeadlinesMarch 7, 2024 | edition.cnn.comImmutep Ltd Sponsored ADRFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immutep on Strong Clinical Pipeline and Market PotentialMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…January 4, 2024 | finance.yahoo.comFirst Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial CancerJanuary 3, 2024 | seekingalpha.comImmutep: Upcoming Signals For 2024 (Maintain Buy)December 24, 2023 | finance.yahoo.comImmutep Limited (IMMP)November 6, 2023 | finance.yahoo.comImmutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast CancerNovember 3, 2023 | finanznachrichten.deImmutep Limited: Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…November 3, 2023 | markets.businessinsider.comImmutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNovember 2, 2023 | finance.yahoo.comImmutep to Participate in November Investor EventsOctober 27, 2023 | markets.businessinsider.comBuy Rating for Immutep (IMMP) Supported by Strong Phase 2 Study Results and Solid Financial PositionOctober 25, 2023 | msn.comImmutep receives about A$1.13M R&D tax incentive from Australian govtOctober 25, 2023 | finance.yahoo.comImmutep receives ~A$1.13 million R&D Tax IncentiveOctober 24, 2023 | finance.yahoo.comImmutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023October 23, 2023 | stockhouse.comImmutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung CancerOctober 22, 2023 | markets.businessinsider.comImmutep : Efti+ Keytruda Generates Excellent OS Benefit In Phase II Trial In Metastatic NSCLCOctober 3, 2023 | finance.yahoo.comImmutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingSeptember 5, 2023 | finance.yahoo.comImmutep to Participate in September Investor ConferencesAugust 30, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on Immutep (IMMP)August 3, 2023 | msn.comImmutep Limited - ADR (IMMP) Price Target Increased by 21.21% to 2.84August 1, 2023 | finance.yahoo.comImmutep Receives Positive Scientific Advice from European Medicines AgencyJune 20, 2023 | finance.yahoo.comImmutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3June 5, 2023 | benzinga.comImmutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual MeetingJune 3, 2023 | au.finance.yahoo.comIMMP - Immutep LimitedJune 2, 2023 | finance.yahoo.comImmutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement OfferMay 18, 2023 | msn.comMaxim Group Maintains Buy Rating for Immutep: Here's What You Need To KnowSee More Headlines Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMMP CUSIPN/A CIK1506184 Webwww.immutep.com Phone(128) 315-7003Fax61-2-8569-1880Employees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+264.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio17.24 Quick Ratio13.81 Sales & Book Value Annual Sales$3.50 million Price / Sales58.54 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book2.24Miscellaneous Outstanding Shares87,930,000Free Float85,231,000Market Cap$204.88 million OptionableOptionable Beta2.15 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Marc Voigt (Age 51)CEO, MD, CFO, Chief Business Officer & Executive Director Comp: $371.23kMs. Deanne Miller LLB (Age 47)COO, General Counsel & Joint Company Secretary Comp: $242.76kDr. Frederic Triebel M.D. (Age 69)Ph.D., Chief Scientific Officer & Executive Director Comp: $296.34kMr. Christian Mueller BBAMSc., Senior Vice President of Regulatory & StrategyMr. Florian D. Vogl M.D.M.Sc., Ph.D., Chief Medical OfficerMs. Indira NaiduJoint Company SecretaryMore ExecutivesKey CompetitorsGeneration BioNASDAQ:GBIOOvid TherapeuticsNASDAQ:OVIDZevra TherapeuticsNASDAQ:ZVRAMerrimack PharmaceuticalsNASDAQ:MACKOmerosNASDAQ:OMERView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 12,198 shares on 2/26/2024Ownership: 0.014%GTS Securities LLCBought 24,596 shares on 2/15/2024Ownership: 0.028%Citadel Advisors LLCSold 3,300 shares on 2/15/2024Ownership: 0.000%Meridian Wealth Management LLCBought 11,250 shares on 2/8/2024Ownership: 0.367%BNP Paribas Financial MarketsBought 6,665 shares on 2/7/2024Ownership: 0.035%View All Institutional Transactions IMMP Stock Analysis - Frequently Asked Questions Should I buy or sell Immutep stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMMP shares. View IMMP analyst ratings or view top-rated stocks. What is Immutep's stock price target for 2024? 1 analysts have issued 12-month target prices for Immutep's stock. Their IMMP share price targets range from $7.00 to $10.00. On average, they expect the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 264.8% from the stock's current price. View analysts price targets for IMMP or view top-rated stocks among Wall Street analysts. How have IMMP shares performed in 2024? Immutep's stock was trading at $2.40 at the start of the year. Since then, IMMP shares have decreased by 2.9% and is now trading at $2.33. View the best growth stocks for 2024 here. Are investors shorting Immutep? Immutep saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,140,000 shares, an increase of 5.6% from the February 29th total of 1,080,000 shares. Based on an average daily volume of 130,400 shares, the short-interest ratio is currently 8.7 days. View Immutep's Short Interest. What other stocks do shareholders of Immutep own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT). Who are Immutep's major shareholders? Immutep's stock is owned by a variety of institutional and retail investors. Top institutional investors include Meridian Wealth Management LLC (0.37%), BNP Paribas Financial Markets (0.03%), GTS Securities LLC (0.03%), Citadel Advisors LLC (0.00%), Virtu Financial LLC (0.01%) and Simplex Trading LLC (0.00%). How do I buy shares of Immutep? Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMMP) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.